we're talking to katherine eban, investigative journalist.er book is just out, and explosive book called "bottle of lies: the inside story of the generic drug boom." back in a minute. ♪ [music break] amy: this is democracy now!, i'm amy goodman. we're spending the hour with investigative journalist katherine eban, author of "bottle of lies: the inside story of the generic drug boom." it has just been published. i want to turn to the indian scientist yusuf hamied, chairman of the drug manufacturer cipla, who shook the conscience of the global health community byby offering to produce generic aids medication at a tiny fraction of the cost. this is dr. hamied speaking severaral years ago. >> you must understand that today in the worldld therere are about 40 millionon hiv-positive. we must also undnderstandd that 8000 plus s are dying every d dy becacause of hiv and related illnesses. jusust whatis not cipla can do, i it is a much wir problem. belveve that the effort requiuired is a team efft for multinatational companies, e government, , governm

. >> it's a window into a larger problem says investigative journalist katherine eban. >> this is alle for the last five years. >> she wrote a book called "bottle of lies." she says the problem is that the u.s. relies on information submitted by drug makers in order to approve their generic medications. but some overseas manufacturers aren't being honest. >> there are many companies in the industry that are falsifying their data. >> falsifying the data. straight out? >> straight-out fraud. >> the first major fraud case came to light 14 years ago. that of indian generic manufacturer ranbaxy. the company paid $500,000 penalty as part of a 2013 settlement for selling adult adulterated drugs and making fraudulent statements to the fda. dinesh thakur was the whistleblower on the case. >> are they the poster child for how bad things could get? >> i wish i could say that i've seen similar behavior in other companies since 2013. >> they're not the only ones? >> no. >> eban says a major part of the problem is the fda's efforts to regulate overseas drug production. >> our entire drug supply has